Abstract
Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.
Highlights
Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers
Tracing its roots back to the 1940s [1], theranostics in nuclear oncology has seen an unprecedented success, mainly due the beneficial effects of such image-guided therapeutic concepts for patients afflicted with radioiodine avid thyroid cancer [2]
Recent years have witnessed an expanded use of novel molecular imaging agents tied to an individually tailored treatment decision [3,4]. Such a theranostic approach enables systemic or locoregional radiation of various cancer entities with mainly β-emitting radionuclides, which are linked to the identical molecule used for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging [4]
Summary
Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. Tracing its roots back to the 1940s [1], theranostics in nuclear oncology has seen an unprecedented success, mainly due the beneficial effects of such image-guided therapeutic concepts for patients afflicted with radioiodine avid thyroid cancer [2]. The more widespread adoption of theranostics is further fueled by the encouraging results of recently published major trials like NETTER-1 for imaging and therapy of neuroendocrine neoplasms (NEN)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
